- Symbol
- CRDF
- Segment MIC
- XNCM
- ISIN
- US14147L1089
- Trading currency
- USD
XNCM:CRDF — listed on NASDAQ CAPITAL MARKET
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for various cancers through PLK1 inhibition. Its lead asset, onvansertib, is a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer. The company's development strategy aims to target tumor vulnerabilities to enhance treatment efficacy.